The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Press release from PR Newswire

Hologic Introduces Synthesized 2D Image Algorithm Designed to Eliminate the Need for a 2D Mammogram in a 2D plus 3D Tomosynthesis Exam

Sunday, November 27, 2011

Hologic Introduces Synthesized 2D Image Algorithm Designed to Eliminate the Need for a 2D Mammogram in a 2D plus 3D Tomosynthesis Exam13:30 EST Sunday, November 27, 2011C-View, the 2D image reconstruction algorithm, is CE Marked and meets the legal requirements for selling the product throughout the European Economic Area and in other countries recognizing the CE MarkBEDFORD, Mass., Nov. 27, 2011 /PRNewswire/ -- Hologic, Inc. (Hologic or the Company) (Nasdaq: HOLX), a leading developer, manufacturer and supplier of premium diagnostic products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, announced today the commercial release of its C-View synthesized 2D image reconstruction algorithm that eliminates the need for a conventional 2D mammogram as a component of a tomosynthesis (3D mammography) breast cancer screening exam. C-View software is approved for sale throughout the European Economic Area and in other countries recognizing the CE Mark. For users of Hologic's 2D plus 3D tomosynthesis breast cancer screening system, C-View software creates a 2D image from a single tomosynthesis scan and eliminates the need for the acquisition of additional 2D exposures. Dr. Stephen Rose, a board certified radiologist with Houston Breast Imaging, one of the first U.S. radiologists to adopt breast tomosynthesis, stated "Hologic's synthesized 2D image reconstruction algorithm is very impressive. C-View provides the information contained in a conventional 2D mammogram without the need for additional exposures while maintaining the superior clinical performance of Hologic's combo-mode (2D plus 3D) imaging." Hologic is featuring the new algorithm along with the Company's Selenia Dimensions breast tomosynthesis system at the Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA), the largest radiology show in the world, taking place at McCormick Place in Chicago November 26 through December 2. Hologic is the global market leader in breast tomosynthesis (3D mammography) with its Selenia Dimensions platform. In Hologic's clinical studies, radiologists reading in combo-mode (2D plus 3D) compared to 2D mammography alone demonstrated superior clinical performance in ruling out breast cancer without recalling the patient for further study and the proportion of mammograms with cancer which were correctly diagnosed. About Hologic, Inc.Hologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostic products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women. Hologic's core business units are focused on breast health, diagnostics, GYN surgical, and skeletal health. Hologic provides a comprehensive suite of technologies with products for mammography and breast biopsy, breast magnetic resonance imaging, radiation treatment for early-stage breast cancer, cervical cancer screening, treatment for menorrhagia and uterine fibroids, permanent contraception, osteoporosis assessment, preterm birth risk assessment, mini C-arm for extremity imaging and molecular diagnostic products including HPV and reagents for a variety of DNA and RNA analysis applications. For more information, visit www.hologic.com.Hologic, C-View, Dimensions and Selenia are trademarks and/or registered trademarks of Hologic, Inc, and/or its subsidiaries in the United States and/or other countries. Forward Looking Statement Disclaimer This News Release may contain forward-looking information that involves risks and uncertainties, including statements about the use of Hologic products. There can be no assurance that the C-View synthesized 2D image reconstruction algorithm when used with a Selenia Dimensions breast tomosynthesis system will achieve the benefits described herein and that such benefits will be replicated in any particular manner with respect to an individual patient as the actual effect of the use of the systems can only be determined on a case-by-case basis depending on the particular circumstances and patient in question. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to the data or statements presented herein to reflect any change in the Company's expectations or any change in events, conditions or circumstances on which any such data or statements are based.Contacts:Olga Karagiannis Jim Culley, PhDCorporate Marketing Corporate MarketingHologic, Inc. Hologic, Inc.Tel: 781.761.7069Olga.karagiannis@hologic.com  Tel: 781.999.7583Jim.culley@hologic.comSOURCE Hologic, Inc.